Bayer Reports Narrowed Loss, Expresses Confidence in Containing Roundup Litigation by 2026
German pharmaceutical and agricultural giant Bayer has struck an optimistic tone regarding its long-running legal battles over the Roundup weedkiller, expressing confidence it can significantly contain the litigation risk by the end of 2026. The announcement accompanied the company’s latest financial results, which showed a substantially narrowed quarterly loss.
Financial Performance Shows Improvement
For the third quarter covering July to September, Bayer reported a net loss of 963 million euros ($1.1 billion). While still a significant figure, this marks a dramatic improvement from the staggering 4.18 billion euro loss recorded during the same period last year.
The company’s underlying performance provided even greater cause for investor optimism. Its operating profit, excluding special items—a key metric closely monitored by the market—surged by approximately 20 percent to reach 1.5 billion euros. This figure comfortably surpassed analyst forecasts, triggering a 3.5 percent rise in Bayer’s share price on the Frankfurt stock exchange.
The Shadow of Glyphosate Litigation
The company’s financials, however, remain heavily influenced by the torrent of legal cases in the United States. These lawsuits allege that Bayer’s glyphosate-based Roundup herbicide causes blood cancer, a claim the company consistently refutes. Bayer maintains that extensive scientific studies and regulatory approvals from agencies worldwide affirm the product’s safety.
Despite the controversy, CEO Bill Anderson struck a determined note. In a company statement, he declared that Bayer is making “significant progress” in managing the legal challenges. “We are confident the company will be able to significantly contain the litigation risk by the end of 2026,” Anderson stated, outlining a clear timeline for resolving a major uncertainty that has clouded the company’s prospects.
A Path Forward Amid Ongoing Challenges
This confidence appears to be partly rooted in a major settlement achieved at the end of July, which Bayer says significantly reduced the number of unresolved glyphosate claims. Nevertheless, the path forward is not without its hurdles.
Anderson acknowledged a “moderate” increase in new case filings following the settlement announcement, a common occurrence in mass tort litigation that has added to legal costs. Yet, the company’s leadership remains steadfast. “Overall, we know that we have a crucial and highly dynamic phase ahead of us,” Anderson noted, emphasizing confidence in the firm’s overarching legal and corporate strategy.
Beyond the courtroom, Bayer’s core business showed resilience. Third-quarter sales reached 9.66 billion euros, propelled by a strong performance in its crop science division and robust demand for new pharmaceutical products. However, the company still booked special charges of around a billion euros during the quarter, a stark reminder that provisions for ongoing litigation continue to weigh heavily on its bottom line.
For more details, read the original article on Legit.ng. Source: AFP